FDA approves Amgen T-cell engager for small cell lung cancer

17 May 2024
·
Deals
www.pharmamanufacturing.com
Phase 2Drug ApprovalClinical ResultAccelerated ApprovalADC
The FDA has approved Amgen’s Imdelltra, a T-cell engager therapy for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) who have experienced disease progression after platinum-based chemotherapy. This marks the first FDA-approved therapy targeting DLL3 in ES-SCLC.
The approval was granted under the FDA's accelerated approval pathway, and continued approval will depend on further verification of clinical benefits in additional trials.
Imdelltra's approval is based on results from the phase 2 DeLLphi-301 clinical trial, which reported a 40% objective response rate, a median duration of response of 9.7 months, and a median overall survival of 14.3 months among patients. The drug works by targeting DLL3, a protein expressed on the surface of SCLC cells, and activating T-cells to attack these tumor cells.
Several drugmakers are currently developing DLL3-targeting therapies for cancer treatment as well; Boehringer Ingelheim is working on BI 764532, a DLL3-targeting T-cell engager for treating small cell lung cancer and other neuroendocrine carcinomas, currently in phase 2 trials. Molecular Partners, in collaboration with Orano Med, is also developing DLL3-targeting therapies, leveraging the protein's expression in tumor cells for selective treatment. Additionally, Zai Lab is investigating ZL-1310, an antibody-drug conjugate targeting DLL3 for solid tumors​.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.